























Filed • Approved  antibody  protein  small molecule

As of Jun.30, 2017

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		<b>KFN321</b> Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Renal Anemia (on Dialysis)	NDA in preparation in CN	Kirin-Amgen	
				Renal Anemia	Filed in ID		
				Myelodysplastic Syndromes	Approved in MY		
		<b>KFN1493</b> Cinacalcet Hydrochloride Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in BN	Licensed from NPS	
		<b>©KHK7580</b> Evocalcet Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in JP	Licensed from Mitsubishi Tanabe Pharma	
Oncology		<b>Granisetron</b> Patch	5-HT <sub>3</sub> Serotonin Receptor Antagonist	Chemotherapy induced Nausea and Vomiting	Filed in MY	Licensed from Solasia Pharma	
Immunology /Allergy		<b>©KHK4563</b> Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma	Filed in JP	In-House	POTELLIGENT® Jointly Developed with AstraZeneca/MedImmune NDA holder is AstraZeneca
		<b>KHK4827</b> Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in TW Filed in TH	Kirin-Amgen	
		<b>Z-206</b> Mesalazine Oral	pH Dependent Controlled Release Tablet	Ulcerative Colitis (Additional Dosage and Administration)	Approved in JP	Licensed from Zeria Pharma	Jointly Developed with Zeria Pharma NDA holder is Zeria Pharma
Other		<b>©KRN23</b> burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH)	Filed in EU	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU

Phase II, Phase III








Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		<b>©RTA 402</b> Bardoxolone Methyl Oral	Antioxidant Inflammation Modulator	CKD in Patients with Type 2 Diabetes	Phase II in JP	Licensed from Reata	
Oncology		<b>©ARQ 197</b> Tivantinib Oral	c-Met Inhibitor	Hepatocellular Cancer	Phase III in JP	Licensed from ArQule	
		<b>KW-0761</b> Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Adult T-cell Leukemia/Lymphoma  Cutaneous T-cell Lymphoma	Phase II in US, EU and others  Phase III in US, EU, JP and others	In-House	POTELLIGENT®
Immunology /Allergy		<b>©KHK4083</b> Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis	Phase II in US, EU and others	In-House	POTELLIGENT® Human Antibody-Producing Technology
		<b>©KHK4563</b> Benralizumab Injection	Anti-IL-5 Receptor Humanized Antibody	Asthma  Chronic Obstructive Pulmonary Disease(COPD)  Eosinophilic Chronic Rhinosinusitis (ECRS)	Phase III in JP and KR  Phase III in JP  Phase II in JP	In-House	POTELLIGENT®  Jointly Developed with AstraZeneca/MedImmune
		<b>KHK4827</b> Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis  Axial Spondyloarthritis (axSpA)	Phase III in KR  Phase III in JP, KR and TW	Kirin-Amgen	
		<b>©ASKP1240</b> Bleselumab Injection	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (IFSGS) in <i>de novo</i> kidney transplant recipients	Phase II in US	In-House	Human Antibody-Producing Technology Jointly Developed with Astellas
		<b>KW-0761</b> Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	Phase III in JP	In-House	POTELLIGENT®
Central Nervous System		<b>KW-6002</b> Istradefylline Oral	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	Phase III in US, CA, EU and others	In-House	
		<b>©KW-6356</b> Oral	Adenosine A <sub>2A</sub> Receptor Antagonist	Parkinson's Disease	Phase II in JP	In-House	
Other		<b>©KRN23</b> burosumab Injection	Anti-FGF23 Fully Human Antibody	X-linked Hypophosphatemia (XLH) in adult patients  X-linked Hypophosphatemia (XLH) in pediatric patients  Tumor Induced Osteomalacia(TIO)/Epide rml Nevus Syndrome (ENS)	Phase III in US, CA, EU, JP and KR  Phase III in US, CA, EU, AU, JP and KR  Phase II in US  Phase II in JP and KR	In-House	Human Antibody-Producing Technology Jointly Developed with Ultragenyx in US and EU
		<b>AMG531</b> Romiplostim Injection	Thrombopoietin Receptor Agonist	Aplastic Anemia  Idiopathic (Immune) Thrombocytopenic Purpura	Phase II / III in JP and KR  Phase III in CN	Kirin-Amgen	

 Updated since Mar 31st, 2017 (Area, Stage, Filed, Approved, etc.)  
 New Molecular Entity

Ph I

 antibody
  protein
  small molecule





As of Jun.30, 2017

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Oncology		©KHK2375 Entinostat Oral	HDAC Inhibitor	Breast Cancer	Phase I in JP	Syndax	
		©KHK2455 Oral	IDO 1 Inhibitor	Solid Tumor	Phase I in US	In-House	Combination with KW-0761
		©KHK2823 Injection	Anti-CD123 Fully Human Antibody	Cancer	Phase I in UK	In-House	POTELLIGENT <sup>®</sup> Human Antibody-Producing Technology
		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	Solid Tumor	Phase I in US	In-House	POTELLIGENT <sup>®</sup>
	Combination with Durvalumab/Tremelimumab (Jointly Developed with AstraZeneca)						
Combination with Docetaxel							
Phase I / II in US	Combination with PF-05082566 (Jointly Developed with Pfizer)						
Phase I in JP	Combination with Nivolumab (Jointly Developed with Bristol-Myers Squibb)						
		Combination with Nivolumab (Jointly Developed with Ono Pharmaceutical)					
Immunology/ Allergy		©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Ulcerative Colitis Atopic Dermatitis	Phase I in JP Phase I in JP	In-House	POTELLIGENT <sup>®</sup> Human Antibody-Producing Technology
Central Nervous System		©KHK6640 Injection	Anti-Amyloid Beta Peptide Antibody	Alzheimer's Disease	Phase I in EU Phase I in JP	Licensed from Immunas Pharma	
Others		KW-3357 Antithrombin Gamma Injection	Recombinant Human Antithrombin	Disseminated Intravascular Coagulation, Congenital Antithrombin Deficiency	Phase I in EU	In-House	




 Updated since Mar 31st, 2017 (Area, Stage, Filed, Approved, etc.)

Updated since Mar 31st, 2017 (Area, Stage, Filed, Approved, etc.)


Filed • Approved

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Nephrology		KRN321 Darbepoetin Alfa Injection	Long-Acting Erythropoiesis Stimulating Agent	Myelodysplastic Syndromes	Approved in MY	Kirin-Amgen	
		©KHK7580 Evocalcet Oral	Calcium Receptor Agonist	Secondary Hyperparathyroidism	Filed in JP	Licensed from Mitsubishi Tanabe Pharma	
Immunology /Allergy		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Psoriasis	Filed in TH	Kirin-Amgen	
		Z-206 Mesalazine Oral	pH Dependent Controlled Release Tablet	Ulcerative Colitis (Additional Dosage and Administration)	Approved in JP	Licensed from Zeria Pharma	Jointly Developed with Zeria Pharma NDA holder is Zeria Pharma

Phase II, Phase III

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Immunology /Allergy		KHK4827 Brodalumab Injection	Anti-IL-17 Receptor A Fully Human Antibody	Axial Spondyloarthritis(axSpA)	Phase III in JP, KR and TW	Kirin-Amgen	
		©ASKP1240 Bleselumab Injection	Anti-CD40 Fully Human Antibody	Recurrence of Focal Segmental Glomerulosclerosis (FSGS) in de novo kidney transplant recipients	Phase II in US	In-House	Human Antibody-Producing Technology Jointly Developed with Astellas
Central Nervous System		KW-0761 Mogamulizumab Injection	Anti-CCR4 Humanized Antibody	HTLV-1 associated myelopathy (HAM)	Phase III in JP	In-House	POTELLIGENT <sup>®</sup>

Ph I

Area		Code Name Generic Name Formulation	Mechanism of Action	Indication	Stage	In-House or Licensed	Remarks
Immunology /Allergy		©KHK4083 Injection	Anti-OX40 Fully Human Antibody	Atopic Dermatitis	Phase I in JP	In-House	POTELLIGENT <sup>®</sup> Human Antibody-Producing Technology